FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022603757> ?p ?o ?g. }

• W2022603757 endingPage "491" @default.
• W2022603757 startingPage "483" @default.
• W2022603757 abstract "Epigallocatechin-3-gallate (EGCG) is the major and most potent polyphenol compound of green tea that has been shown to have anticancer effects against various types of cancers. In this study, in addition to the EGCG compound, a synthetic derivative, the peracetate of EGCG (EGCG-P), was used to investigate the inhibitory effects on growth of androgen-independent prostate cancer in vivo. The advantage of EGCG-P is that it may act as a prodrug, leading to higher bioavailability than EGCG itself. The aim of our study was to compare the differences between EGCG and EGCG-P on their inhibitory effect on androgen-independent prostate cancer, CWR22R, xenograft model in nude mice. The mice were administrated daily with solvent dimethyl sulfoxide, EGCG, and EGCG-P separately through intraperitoneal injection for 20 days. Tumor volume and body weight of nude mice were recorded daily. Serum prostate-specific antigen (PSA) levels were also measured before and after the treatment. The effects of both EGCG and EGCG-P on tumor cell proliferation were assessed by immunohistochemical (IHC) method using antibodies against Ki-67 and proliferating cell nuclear antigen. The apoptotic effect was evaluated by IHC against B-cell non-Hodgkin lymphoma-2 and terminal deoxynucleotidyl transferase dUTP nick-end labeling assay by in situ apoptosis detection kit. Moreover, the potential suppression of angiogenesis by EGCG and EGCG-P on prostate cancer was examined by IHC against CD31. Our results revealed that treatment of EGCG and EGCG-P compounds suppressed the growth of CWR22R xenografts without causing any detectable side effects in nude mice. The suppression of growth of the tumor was correlated with the decrease of serum PSA level together with the reduction in tumor angiogenesis and an increase in apoptosis on prostate cancer cells. The results showed that treatment of EGCG and EGCG-P inhibited tumor growth and angiogenesis while promoting apoptosis of the prostate cancer cells in vivo. Our results suggest that EGCG-P may be a more stable and useful compound for increasing the therapeutic anticancer effects in androgen-independent prostate cancer." @default.
• W2022603757 created "2016-06-24" @default.
• W2022603757 creator A5009162821 @default.
• W2022603757 creator A5024405409 @default.
• W2022603757 creator A5029380556 @default.
• W2022603757 creator A5042410582 @default.
• W2022603757 creator A5049670589 @default.
• W2022603757 creator A5078521916 @default.
• W2022603757 creator A5082252273 @default.
• W2022603757 date "2008-06-26" @default.
• W2022603757 modified "2023-09-30" @default.
• W2022603757 title "Effect of a Prodrug of the Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate on the Growth of Androgen-Independent Prostate Cancer In Vivo" @default.
• W2022603757 cites W129768452 @default.
• W2022603757 cites W1541258385 @default.
• W2022603757 cites W1973303608 @default.
• W2022603757 cites W1974797818 @default.
• W2022603757 cites W1996644309 @default.
• W2022603757 cites W2003825045 @default.
• W2022603757 cites W2009686658 @default.
• W2022603757 cites W2011608085 @default.
• W2022603757 cites W2012970858 @default.
• W2022603757 cites W2016313181 @default.
• W2022603757 cites W2023018072 @default.
• W2022603757 cites W2034269086 @default.
• W2022603757 cites W2034469468 @default.
• W2022603757 cites W2036809593 @default.
• W2022603757 cites W2044087374 @default.
• W2022603757 cites W2051039369 @default.
• W2022603757 cites W2072119701 @default.
• W2022603757 cites W2087591994 @default.
• W2022603757 cites W2095568326 @default.
• W2022603757 cites W2099156776 @default.
• W2022603757 cites W2100380559 @default.
• W2022603757 cites W2101266541 @default.
• W2022603757 cites W2108363571 @default.
• W2022603757 cites W2117141623 @default.
• W2022603757 cites W2117215465 @default.
• W2022603757 cites W2136816004 @default.
• W2022603757 cites W2142285790 @default.
• W2022603757 cites W2142693119 @default.
• W2022603757 cites W2154471277 @default.
• W2022603757 cites W2314755674 @default.
• W2022603757 doi "https://doi.org/10.1080/01635580801947674" @default.
• W2022603757 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18584482" @default.
• W2022603757 hasPublicationYear "2008" @default.
• W2022603757 type Work @default.
• W2022603757 sameAs 2022603757 @default.
• W2022603757 citedByCount "66" @default.
• W2022603757 countsByYear W20226037572012 @default.
• W2022603757 countsByYear W20226037572013 @default.
• W2022603757 countsByYear W20226037572014 @default.
• W2022603757 countsByYear W20226037572015 @default.
• W2022603757 countsByYear W20226037572016 @default.
• W2022603757 countsByYear W20226037572017 @default.
• W2022603757 countsByYear W20226037572018 @default.
• W2022603757 countsByYear W20226037572019 @default.
• W2022603757 countsByYear W20226037572020 @default.
• W2022603757 countsByYear W20226037572022 @default.
• W2022603757 countsByYear W20226037572023 @default.
• W2022603757 crossrefType "journal-article" @default.
• W2022603757 hasAuthorship W2022603757A5009162821 @default.
• W2022603757 hasAuthorship W2022603757A5024405409 @default.
• W2022603757 hasAuthorship W2022603757A5029380556 @default.
• W2022603757 hasAuthorship W2022603757A5042410582 @default.
• W2022603757 hasAuthorship W2022603757A5049670589 @default.
• W2022603757 hasAuthorship W2022603757A5078521916 @default.
• W2022603757 hasAuthorship W2022603757A5082252273 @default.
• W2022603757 hasConcept C121608353 @default.
• W2022603757 hasConcept C126322002 @default.
• W2022603757 hasConcept C150903083 @default.
• W2022603757 hasConcept C154113507 @default.
• W2022603757 hasConcept C185592680 @default.
• W2022603757 hasConcept C190283241 @default.
• W2022603757 hasConcept C196795494 @default.
• W2022603757 hasConcept C207001950 @default.
• W2022603757 hasConcept C2776235491 @default.
• W2022603757 hasConcept C2777192995 @default.
• W2022603757 hasConcept C2777926168 @default.
• W2022603757 hasConcept C2778004101 @default.
• W2022603757 hasConcept C2780192828 @default.
• W2022603757 hasConcept C2780394083 @default.
• W2022603757 hasConcept C2992814287 @default.
• W2022603757 hasConcept C31903555 @default.
• W2022603757 hasConcept C502942594 @default.
• W2022603757 hasConcept C55493867 @default.
• W2022603757 hasConcept C62112901 @default.
• W2022603757 hasConcept C70899900 @default.
• W2022603757 hasConcept C71924100 @default.
• W2022603757 hasConcept C86803240 @default.
• W2022603757 hasConcept C98274493 @default.
• W2022603757 hasConceptScore W2022603757C121608353 @default.
• W2022603757 hasConceptScore W2022603757C126322002 @default.
• W2022603757 hasConceptScore W2022603757C150903083 @default.
• W2022603757 hasConceptScore W2022603757C154113507 @default.
• W2022603757 hasConceptScore W2022603757C185592680 @default.
• W2022603757 hasConceptScore W2022603757C190283241 @default.
• W2022603757 hasConceptScore W2022603757C196795494 @default.
• W2022603757 hasConceptScore W2022603757C207001950 @default.

• next